General
Preferred name
CRISABOROLE
Synonyms
AN-2728 ()
PF-06930164 ()
AN2728 ()
Crisaborole (AN2728) ()
AN2728 ()
Staquis ()
Crisaborol ()
Eucrisa ()
P&D ID
PD012854
CAS
1073669-75-6
906673-24-3
Tags
available
drug
Approved by
FDA
EMA
First approval
2016
Drug indication
atopic eczema
Atopic dermatitis
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 ¦ÌM.
PRICE 31
DESCRIPTION Crisaborole is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor acting primarily against the PDE4B isozyme . It was developed by Anacor Pharmaceuticals for its potential anti-inflammatory action in skin conditions such as psoriasis and atopic dermatitis. (GtoPdb)
DESCRIPTION Crisaborole has broad-spectrum anti-inflammatory activity by mainly targeting phosphodiesterase 4 (PDE4) enzyme that is a key regulator of inflammatory cytokine production. It is intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. (Enamine Bioactive Compounds)
DESCRIPTION Crisaborole (AN-2728) is a phosphodiesterase 4 inhibitor. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
27
AdooQ Bioactive Compound Library
A12776
Axon Medchem Screening Library
3169
Cayman Chemical Bioactives
21455
ChEMBL Approved Drugs
CHEMBL484785
ChEMBL Drugs
CHEMBL484785
Concise Guide to Pharmacology 2017/18
9151
Concise Guide to Pharmacology 2019/20
9151
Concise Guide to Pharmacology 2021/22
9151
Concise Guide to Pharmacology 2023/24
9151
Drug Repurposing Hub
DrugBank
DB05219
DrugBank Approved Drugs
DB05219
DrugCentral
5201
DrugCentral Approved Drugs
5201
DrugMAP
DMNVKU6
DrugMAP Approved Drugs
DMNVKU6
Enamine Bioactive Compounds
EBC-26322
EU-OPENSCREEN Bioactive Compound Library
EOS101135
Guide to Pharmacology
9151
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL484785
Mcule NIBR MoA Box Subset
MCULE-6401448326
MedChem Express Bioactive Compound Library
HY-10978
NCATS Inxight Approved Drugs
Q2R47HGR7P
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
crisaborole-an2728
TargetMol Bioactive Compound Library
T4285
External IDs
29
Properties
(calculated by RDKit )
Molecular Weight
251.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
1.57
TPSA
62.48
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
PDE4
phosphodiesterase
PDE4A, PDE4B, PDE4C, PDE4D
PDE4 inhibitor
PDE
Phosphodiesterase (PDE)
Member status
member
MOA
PDE4 inhibitor use for topical application
phosphodiesterase inhibitor
Indication
dermatitis
Pathway
Metabolism
Metabolic Enzyme/Protease
Source data